Former Chief Executive Officer · Terns Pharmaceuticals, Inc. (TERN)

Senthil Sundaram

A named executive officer of Terns Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$6,765,408

Salary $374,398Stock awards $0

FY2022: $1,966,636

1st of 4 named executive officers at Terns Pharmaceuticals by FY2023 total.

4 named officers on file for Terns Pharmaceuticals, FY2023

Senthil Sundaram’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Terns Pharmaceuticals’s whole pay program stands against its peers

  • Terns Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TERN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A).

Free

Get Senthil Sundaram’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Senthil Sundaram compensation by year

Terns Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Terns Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$561,400$374,398
Bonus$0$0
Stock awards$0$0
Option awards$971,986$5,407,180
Non-equity incentive$421,050$301,150
Pension and deferred compensation$0$0
All other$12,200$682,680
Total$1,966,636$6,765,408

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Terns Pharmaceuticals, Inc. DEF 14A filed April 25, 2024, accession 0000950170-24-048289, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Terns Pharmaceuticals, Inc. filed document, accession 0000950170-24-048289. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

$2.0M
$6.8M
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Terns Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Senthil Sundaram · this pageFormer Chief Executive Officer$6,765,408
Erin QuirkFormer President, Head of Research & Development$4,665,845
Mark VignolaFormer Chief Financial Officer and Treasurer$3,137,032
Bryan YoonChief Operating Officer, General Counsel and Secretary$3,083,918

The full Terns Pharmaceuticals compensation record

free company brief

This page is one person within Terns Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Terns Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Senthil Sundaram's compensation dossier · One-time report. No refunds.